Rui M. Silva-Santos1,2, Pedro Costa-Pinheiro1,2*, Ana Luís1,3*, Luís Antunes4, Francisco Lobo5, Jorge Oliveira5, Rui Henrique1,3,6, Carmen Jerónimo1,2,6* 1.Cancer Epigenetics Group, Research Center of the Portuguese Oncology Institute, Porto, Portugal; Departments of 2.Genetics, 3.Pathology, 4.Epidemiology and 5.Urology - Portuguese Oncology Institute, Porto, Portugal; 6.Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Portugal
